Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Black currant oil

This article was originally published in The Tan Sheet

Executive Summary

In an Aug. 11 letter to Rep. Henry Waxman (D-Calif.), Traco Labs noted the "dramatic difference between what FDA told Congress about" BCO in a May 19 enforcement report on dietary supplements and "what they now state and confirm in response to" a Freedom of Information Act request from Traco. The firm submitted an Fol request to FDA in June asking for documentation to support a statement in the FDA report that gama linolenic acid, a component of BCO, poses serious health concerns ("The Tan Sheet" May 31, p. 3). FDA responded to Traco on Aug. 5 that "we have searched our files and find no responsive information or documents" to support the claim that gama linolenic acid is unsafe.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS081793

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel